Church & Dwight
CHD
$96.14
+0.88%
Church & Dwight Co., Inc. is a leading consumer packaged goods company operating in the Household & Personal Products industry, best known as the global producer of Arm & Hammer baking soda and a portfolio of brands including OxiClean, Vitafusion, and TheraBreath. The company has established a distinct competitive identity as a value-driven, brand-focused player that leverages its core baking soda platform to expand into adjacent categories like laundry, oral care, and cat litter, deriving approximately 80% of its sales from the stable US market. The current investor narrative centers on the company's ability to navigate a challenging consumer environment with its value-oriented offerings, while integrating recent acquisitions like Touchland and demonstrating resilience through modest organic growth, as evidenced by its latest quarterly revenue increase.…
CHD
Church & Dwight
$96.14
Investment Opinion: Should I buy CHD Today?
Rating & Thesis: Hold. CHD is a financially sound, defensive company currently trading at a premium valuation that appears fully priced given its modest growth trajectory and recent margin pressure, warranting a neutral stance until a more attractive entry point emerges or fundamentals improve.
Supporting Evidence: The forward P/E of 23.85x, while lower than the trailing 27.62x, remains elevated for a company with decelerating revenue growth (3.93% in Q4). Profitability is strong but trending down, with net margin at 11.88% and operating margin declining sequentially. The robust free cash flow ($1.09B) and high ROE (18.41%) are positive, but are already reflected in the price. The stock's significant underperformance (-30.77 relative strength over 1 year) suggests the market is already discounting these concerns.
Risks & Conditions: The two biggest risks are further margin erosion and a de-rating of its premium P/E multiple. This Hold rating would upgrade to a Buy if the P/E compresses meaningfully below 20x (offering a margin of safety) or if quarterly revenue growth re-accelerates sustainably above 5% with stable margins. It would downgrade to a Sell if operating margins fall below 15% or if the stock breaks below its 52-week low of $81.33 on deteriorating fundamentals. Relative to its own history and the sector, the stock is currently overvalued.
Sign up to view all
CHD 12-Month Price Forecast
The outlook for CHD is one of stable, low-growth consolidation. The base case (60% probability) of range-bound trading is most likely, as the stock's premium valuation offsets its defensive qualities and strong cash generation. The bear case risk is elevated due to the high starting P/E and margin pressures, but the company's financial strength provides a floor. The bull case requires a reacceleration of growth that recent data does not support. The stance would upgrade to bullish on a sustained break above $106 with improving margins, or turn bearish on a confirmed break below the $81 support level.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Church & Dwight's 12-month outlook, with a consensus price target around $124.98 and implied upside of +30.0% versus the current price.
Average Target
$124.98
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$77 - $125
Analyst target range
Analyst coverage for CHD is limited, with data indicating only 5 analysts providing estimates for future EPS and revenue, which suggests the stock may have less institutional scrutiny typical of a mid-cap company. The consensus sentiment appears neutral to cautiously optimistic, as evidenced by recent institutional rating actions including a mix of 'Hold', 'Neutral', and 'Buy' recommendations, with specific firms like Jefferies maintaining a 'Buy' and JP Morgan upgrading from 'Underweight' to 'Neutral' in early February 2026. Without a provided average target price, the implied upside cannot be calculated, but the narrow range of estimated EPS for the next period ($4.72 low to $4.81 high) indicates analysts have relatively high conviction in the company's near-term earnings power, though the wide dispersion in stock price targets is not available from the data to assess uncertainty.
Bulls vs Bears: CHD Investment Factors
The evidence is currently balanced but tilts bearish due to valuation and momentum concerns. The bull case is anchored in the company's financial strength, high profitability, and defensive nature, which are compelling for a stable portfolio holding. The bear case is driven by a premium valuation in the face of decelerating growth and clear technical underperformance. The single most important tension in the investment debate is whether the company's premium P/E multiple of 27.6x can be justified by its modest ~4% revenue growth and contracting margins, or if a further derating is inevitable.
Bullish
- Strong Cash Flow & Profitability: The company generates robust free cash flow of $1.09B TTM, supporting a healthy dividend with a 39% payout ratio. This provides financial flexibility for reinvestment and shareholder returns, underpinning a resilient business model.
- Conservative Balance Sheet: A low debt-to-equity ratio of 0.55 and a current ratio of 1.07 indicate a strong, conservatively managed financial position. This reduces refinancing risk and provides a buffer against economic downturns.
- High Return on Equity: An ROE of 18.41% demonstrates efficient use of shareholder capital and superior profitability compared to many peers. This supports the company's premium valuation and ability to generate shareholder value.
- Stable US Market Focus: Approximately 80% of sales are derived from the stable US market, providing predictable revenue streams. The 3.93% YoY revenue growth in Q4 2025, while modest, shows resilience in a challenging consumer environment.
Bearish
- Premium Valuation vs. Peers: A trailing P/E of 27.62x is at a significant premium to typical consumer defensive stocks. This high multiple leaves little room for error and makes the stock vulnerable to valuation compression if growth disappoints.
- Significant Underperformance vs. Market: The stock has a 1-year relative strength of -30.77, significantly underperforming the S&P 500. This indicates persistent negative investor sentiment and a lack of positive catalysts to drive outperformance.
- Decelerating Growth & Margin Pressure: Q4 2025 revenue growth of 3.93% shows a deceleration from earlier quarters. Furthermore, the operating margin fell to 16.18% in Q4 from 20.13% in Q1 2025, indicating rising cost pressures or competitive challenges.
- Limited Analyst Coverage & Conviction: Only 5 analysts provide estimates, suggesting limited institutional scrutiny. While recent ratings are mixed (e.g., JP Morgan upgrade to Neutral), the lack of a clear, strong consensus target price reflects uncertainty about the near-term path.
CHD Technical Analysis
The stock is in a sustained downtrend over the medium term, with a 1-year price change of -2.56% and a more pronounced 3-month decline of -8.80%, underperforming the broader market significantly as indicated by a -30.77 relative strength over the past year. Currently trading at $95.63, the price sits approximately 47% above its 52-week low of $81.33 and 10% below its 52-week high of $106.04, positioning it in the lower-middle of its annual range and suggesting the momentum has cooled from earlier highs but a deep value opportunity has not yet been presented. Recent momentum shows conflicting signals, with a slight 1-month decline of -0.59% that is notably less severe than the 3-month drop, hinting at a potential stabilization or deceleration of the sell-off, especially when considering the stock's low beta of 0.482 implies it is roughly 52% less volatile than the market, which may cushion further declines. Key technical levels are clearly defined with immediate support at the $81.33 low and resistance near the $106.04 high; a decisive break below support could signal a continuation of the downtrend towards lower valuations, while a reclaim of the $100 level would be necessary to suggest a recovery is underway, with the stock's low beta indicating it should exhibit less dramatic swings than the overall market during this consolidation phase.
Beta
0.48
0.48x market volatility
Max Drawdown
-18.1%
Largest decline past year
52-Week Range
$81-$106
Price range past year
Annual Return
-2.9%
Cumulative gain past year
| Period | CHD Return | S&P 500 |
|---|---|---|
| 1m | +0.1% | +5.4% |
| 3m | -6.2% | +10.9% |
| 6m | +14.5% | +11.0% |
| 1y | -2.9% | +28.1% |
| ytd | +16.3% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CHD Fundamental Analysis
Revenue growth is positive but modest, with the most recent Q4 2025 revenue of $1.644 billion representing a 3.93% year-over-year increase, though this marks a deceleration from the stronger growth seen in prior quarters of fiscal 2025 (Q1: $1.467B, Q2: $1.506B, Q3: $1.586B). The company remains solidly profitable, reporting net income of $143.5 million for Q4 2025 and a trailing twelve-month net margin of 11.88%, supported by a healthy gross margin of 44.73% as of the latest valuation data, which is consistent with its consumer staples peers. Profitability metrics have shown some quarterly fluctuation, with Q4 2025 operating income of $266 million and operating margin of 16.18%, which is down from the 20.13% margin in Q1 2025, indicating some margin pressure likely from input cost inflation or competitive dynamics. The balance sheet is conservatively managed with a debt-to-equity ratio of 0.55, indicating a moderate use of leverage, and the company generates robust cash flow, evidenced by a trailing free cash flow of $1.093 billion and a current ratio of 1.07, providing ample liquidity to fund operations, dividends (payout ratio of 38.98%), and share repurchases without straining its financial position.
Quarterly Revenue
$1.6B
2025-12
Revenue YoY Growth
+0.03%
YoY Comparison
Gross Margin
+0.45%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CHD Overvalued?
Given the company's consistent profitability with a positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 27.62x and a forward PE of 23.85x, with the forward multiple being 14% lower, implying the market expects modest earnings growth in the coming year. Compared to sector averages, Church & Dwight's trailing PE of 27.62x represents a significant premium; while a direct industry average PE is not provided in the data, the stock's valuation is elevated relative to typical consumer defensive names, which may be justified by its strong brand portfolio, high returns on equity (18.41%), and stable cash flow generation, but also suggests limited margin for multiple expansion. Historically, the current trailing PE of 27.62x is below the stock's own recent peak of 34.87x seen at the end of Q4 2025 but above the lower end of its historical range observed in prior years, indicating the valuation has compressed from recent highs but is not yet at deeply discounted levels, reflecting a market that is pricing in steady performance rather than explosive growth.
PE
27.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -85x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is margin compression, as evidenced by the Q4 2025 operating margin of 16.18%, down nearly 400 basis points from Q1 2025's 20.13%. While the balance sheet is conservative (D/E of 0.55), the company's valuation is highly dependent on maintaining premium profitability metrics like its 18.4% ROE. Revenue concentration in the mature US market (~80% of sales) limits geographic diversification, making growth reliant on market share gains in a competitive landscape, which is challenging given the modest 3.9% YoY revenue increase.
Market & Competitive Risks: The stock's primary market risk is valuation compression. Trading at a trailing P/E of 27.6x, it commands a significant premium to the sector. If investor appetite for defensive, slower-growth stocks wanes or if interest rates remain elevated, this multiple could contract towards historical or peer averages, pressuring the share price. This is reflected in the stock's severe underperformance (1-year relative strength of -30.77) despite its low beta of 0.48. Competitive risks include private label incursion and pricing pressure in its core categories like laundry and oral care.
Worst-Case Scenario: A confluence of sustained input cost inflation, failed price realization, and market share loss to competitors could lead to consecutive quarters of margin contraction and organic growth stagnation. This would trigger multiple compression as the market reassesses the growth premium. Analyst downgrades and outflows from defensive sectors could accelerate the decline. A realistic downside scenario could see the stock re-test its 52-week low of $81.33, representing a potential loss of approximately -15% from the current price of $95.63.
FAQ
The key risks are: 1) Valuation Compression: The high P/E multiple (27.6x trailing) is vulnerable to derating if growth slows further, posing a ~15% downside to the 52-week low. 2) Margin Erosion: Operating margin fell nearly 400 bps in FY2025; sustained input cost inflation or competitive pressure could further compress profitability. 3) Low Growth: Revenue growth of 3.93% is modest for a premium-priced stock, limiting upside catalysts. 4) Market Sentiment: The stock has severely underperformed the S&P 500 (-30.77 over 1 year), indicating persistent negative momentum that could continue.
The 12-month forecast for CHD is a range-bound, low-conviction outlook. The base case (60% probability) sees the stock trading between $95 and $105 as it grinds out modest earnings growth with a stable P/E. The bull case (20% probability) targets $106 to $115 on margin recovery and multiple expansion. The bear case (20% probability) sees a decline to $81-$90 on further margin pressure and multiple compression. The most likely scenario is the base case, predicated on the assumption that the company's strong cash flows and defensive profile prevent a severe decline, but its premium valuation and slowing growth cap meaningful upside.
CHD stock is overvalued relative to its growth prospects. It trades at a forward P/E of 23.85x and a trailing P/E of 27.62x, a significant premium to the broader consumer staples sector. This valuation implies the market expects steady mid-single-digit earnings growth and sustained high profitability. However, with quarterly revenue growth decelerating to 3.93% and operating margins declining from 20.13% to 16.18% over fiscal 2025, the current multiple is not justified by the underlying business momentum. The stock is fairly valued only if one assigns a high premium for its defensive low-beta characteristics and strong balance sheet.
CHD is not an compelling buy at the current price of $95.63. While the company has strong fundamentals including robust free cash flow ($1.09B) and a high ROE (18.41%), its premium forward P/E of 23.85x appears stretched given its decelerating revenue growth (3.93% in Q4) and contracting operating margins. The stock has significantly underperformed the market (-30.77 relative strength over 1 year), indicating negative sentiment. It could be a good buy for a very patient, income-oriented investor only on a meaningful pullback towards the $85-$90 range, offering a better margin of safety.
CHD is primarily suitable for a long-term (3-5 year) investment horizon. Its low beta (0.48) and stable cash flows make it a poor candidate for short-term trading, as it lacks the volatility and catalyst-driven price action. For the long-term investor, the company's strong brands, high ROE (18.41%), and consistent dividend (1.4% yield, 39% payout ratio) support a buy-and-hold strategy focused on capital preservation and income. However, given the current valuation, new investors should consider dollar-cost averaging or waiting for a more attractive entry point below $90 to improve long-term returns.